摘要
目的观察固本咳喘颗粒对实验性慢性阻塞性肺疾病(COPD)大鼠转化生长因子-β1(TGF-β1)mRNA的表达的水平,探讨其干预作用及机制。方法采用烟熏加气管内滴注脂多糖(LPS)建立实验性COPD大鼠模型,随机分为6组,即正常对照组(8只),模型对照组(9只),固本咳喘颗粒大(9只)、中(8只)、小剂量组(7只),固本咳喘片组(8只)。从造模的第3 d开始,正常对照组和模型对照组灌服0.9%氯化钠注射液10 mL/kg,固本咳喘颗粒大、中、小剂量组分别灌服固本咳喘颗粒混悬液2.28、11.4、5.7 g/kg(2.28、1.14、0.57 g/mL),固本咳喘片组灌服固本咳喘片混悬液75 mg/kg(7.5 mg/mL),均每日1次灌胃,连续灌胃28 d,灌胃结束第2 d处死大鼠,采取标本,采用半定量逆转录聚合酶链反应(RT-PCR)法检测大鼠肺组织中TGF-β1mRNA表达情况。结果固本咳喘颗粒大、小剂量组TGF-β1mRNA表达阳性细胞百分率,与模型对照组比较差异均有统计学意义(P<0.01),固本咳喘颗粒小剂量组TGF-β1mRNA表达阳性细胞百分率与固本咳喘片组,固本咳喘颗粒大、中剂量组比较差异均有统计学意义(P<0.01)。结论固本咳喘颗粒可通过调控TGF-β1mRNA,从而减轻实验性COPD大鼠气道炎症和慢性损伤。
Objective To observe the effect of Guben Kechuan Granules on expression level of TGF-β1mRNA of rats with experimental chronic obstructive pulmonary disease（COPD） and study its intervention effect and mechanism.Methods Experimental rat models with COPD made by fumigation and dripping Lipopolysaccharide（LPS） into tracheae were randomly divided into 6 groups： normal control group,model control group,high dose Guben Kechuan Granules group,middle dose Guben Kechuan Granules group,low dose Guben Kechuan Granules group and Guben Kechuan Tablets group.From the third day of modeling,medicines were administered to rats by means of intragastric administration for consecutive 28 days.Two days after the finishing of intragastric administration,rats were executed and samples were collected.TGF-β1mRNA expression level in rat lung tissues was tested by means of semiquantitative RT-PCR method.Results The percentage of TGF-β1mRNA positive cells in high-dose and low-dose groups of Guben Kechuan Granules decreased obviously,with a significant difference compared with model group（P〈0.01）.Conclusion Guben Kechuan Granules can relieve inflammation and chronic lesion in the airway of rats with experimental COPD by regulating TGF-β1mRNA expression level.
出处
《河北中医》
2010年第11期1705-1707,F0003,共4页
Hebei Journal of Traditional Chinese Medicine
基金
江苏省中医药管理局2005-2006年度中医药科研项目(第1批)(编号:H05033)
关键词
肺疾病
阻塞性
中药疗法
疾病模型
动物
转化生长因子-Β
Chronic obstructive pulmonary disease
Traditional Chinese medicine therapy
Animal disease models
TGF-β1
